



## Erratum

**To cite this article:** (2010) Erratum, Expert Opinion on Pharmacotherapy, 11:1, 167-167, DOI: [10.1517/14656560903467712](https://doi.org/10.1517/14656560903467712)

**To link to this article:** <https://doi.org/10.1517/14656560903467712>



Published online: 10 Dec 2009.



Submit your article to this journal [↗](#)




Article views: 247



View related articles [↗](#)

In the drug evaluation “Tapentadol immediate release for the relief of moderate-to-severe acute pain” by Hartrick C published in the November issue of *Expert Opinion on Pharmacotherapy* (*Expert Opin. Pharmacother.* 2009;10(16):2687-2696), Box 1 and the credit lines for Tables 2 and 3 and Figure 1 should have appeared as follows:

| Box 1. Drug summary.     |   |
|--------------------------|---|
| Drug name                | Tapentadol IR   |
| Phase                    | Launched  |
| Indication               | Moderate to severe acute pain   |
| Pharmacology description | $\mu$ -Opioid receptor agonist and norepinephrine reuptake inhibitor  |
| Route of administration  | Alimentary, p.o.  |
| Chemical structure       |    |
| Pivotal trial(s)         | Four Phase III trials of patients with moderate to severe acute postoperative pain, osteoarthritis pain, and/or low back pain have been conducted. Data suggested that the efficacy of tapentadol IR 50, 75, or 100 mg every 4 – 6 h was similar to that of oxycodone HCl IR 10 or 15 mg every 4 – 6 h with improved gastrointestinal tolerability. |

Pharmaprojects - Copyright to Citeline Drug Intelligence (an Informa business). Readers are referred to Informa-Pipeline (<http://informa-pipeline.citeline.com>) and Citeline (<http://informa.citeline.com>).

Table 2: Adapted by permission from Informa Healthcare: *Curr Med Res Opin.* 24(11):3185-96 [39]. Copyright 2008 Informa.

Table 3: Adapted by permission from Informa Healthcare: *Curr Med Res Opin.* 25(6):1551-61 [42]. Copyright 2009 Informa.

Figure 1: Reproduced with permission from Hale, et al. *Curr Med Res Opin.* 2009;25(5):1095-104 [41].

The publishers, editors and author regret any inconvenience this may have caused.